Unknown

Dataset Information

0

Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies.


ABSTRACT: Background:In recent years, investigators have asserted that the 3?+?3 design lacks flexibility, making its use in modern early-phase trial settings, such as combinations and/or biological agents, inefficient. More innovative approaches are required to address contemporary research questions, such as those posed in trials involving immunotherapies. Design:We describe the implementation of an adaptive design for identifying an optimal treatment regimen, defined by low toxicity and high immune response, in an early-phase trial of a melanoma helper peptide vaccine plus novel adjuvant combinations. Results:Operating characteristics demonstrate the ability of the method to effectively recommend optimal regimens in a high percentage of trials with reasonable sample sizes. Conclusions:The proposed design is a practical, early-phase, adaptive method for use with combined immunotherapy regimens. This design can be applied more broadly to early-phase combination studies, as it was used in an ongoing study of two small molecule inhibitors in relapsed/refractory mantle cell lymphoma.

SUBMITTER: Wages NA 

PROVIDER: S-EPMC5834099 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies.

Wages N A NA   Slingluff C L CL   Petroni G R GR  

Annals of oncology : official journal of the European Society for Medical Oncology 20170401 4


<h4>Background</h4>In recent years, investigators have asserted that the 3 + 3 design lacks flexibility, making its use in modern early-phase trial settings, such as combinations and/or biological agents, inefficient. More innovative approaches are required to address contemporary research questions, such as those posed in trials involving immunotherapies.<h4>Design</h4>We describe the implementation of an adaptive design for identifying an optimal treatment regimen, defined by low toxicity and  ...[more]

Similar Datasets

| S-EPMC5834117 | biostudies-literature
| S-EPMC6649924 | biostudies-literature
| S-EPMC6952569 | biostudies-literature
| S-EPMC4380742 | biostudies-literature
| S-EPMC4701120 | biostudies-literature
| S-EPMC4648610 | biostudies-other
| S-EPMC6875515 | biostudies-literature
| S-EPMC4258389 | biostudies-literature
| S-EPMC11371698 | biostudies-literature
| S-EPMC5834138 | biostudies-other